Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

• Published in: World journal of surgical oncology Vol. 20; no. 1; pp. 1 - 229
• Main Authors: Bi, Yonghua, Jiao, Dechao, Wang, Yang, Han, Xinwei, Ren, Jianzhuang
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.07.2022; BioMed Central; BMC
• Subjects: Abdomen; Adenocarcinoma; Adverse events; Callispheres® beads; Cancer therapies; Cardiotoxicity; Care and treatment; Catheters; Chemoembolization; Chemotherapy; Colorectal cancer; Confidence intervals; DEB-TACE; Diagnosis; Disease control; Drug delivery; Drug-eluting stents; Efficiency; Embolization; Fever; Gastrointestinal adenocarcinoma; Gastrointestinal tumors; Health aspects; Health services; Hepatectomy; Hepatocellular carcinoma; Liver; Liver cancer; Liver metastasis; Magnetic resonance imaging; Medical prognosis; Metastases; Metastasis; Nausea; Pain; Patient outcomes; Patients; Pharmaceuticals; Polyvinyl alcohol; Prevention; Raltitrexed; Response rates; Risk factors; Survival; Therapeutic chemoembolization; Tomography; Tumors; Veins & arteries; Vomiting; China
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-022-02696-x

Background Drug-eluting bead transarterial chemoembolization (DEB-TACE) with Callispheres[R] beads (CB) is currently used in the treatment of hepatocellular carcinoma. However, clinical data regarding DEB-TACE using raltitrexed-eluting CB for gastrointestinal adenocarcinoma liver metastases (GALM) treatment is limited. We aimed to report the preliminary outcomes of DEB-TACE using CB in unresectable GALM patients. Methods This retrospective study enrolled unresectable GALM patients who were treated with DEB-TACE using raltitrexed-eluting CB from October 2018 to October 2021. Totally, 25 patients, 18 males and 7 females, mean age 66.8[+ or -]9.5 years, were continuously enrolled. Postoperative treatment response, survival rates, and complication were calculated during the procedure and follow-up. Results Twenty-four patients were technically successful, with a technical success rate of 96.0%. The 3-month overall response rate and disease control rate were 21.7% and 73.9%, and 6-month overall response rate and disease control rate were 30.0% and 65.0%. The median survival time from diagnosis of GALM was 31.3 months. The median survival time and median PFS from first DEB-TACE was 21.3 months (95% confidence interval 9.1-33.5) and 10.7 months (3.7-17.7), respectively. Main adverse events included abdominal pain (36.0%), fever (12.0%), and nausea/vomiting (28.0%) after DEB-TACE. No treatment-related deaths and grade 3 or grade 4 adverse events were observed. Conclusions DEB-TACE using raltitrexed eluting CB was demonstrated as a safe and efficient alternative choice for GALM. Keywords: Liver metastasis, DEB-TACE, Raltitrexed, Gastrointestinal adenocarcinoma, Callispheres[R] beads